MedTrace Logo

Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution

NCT07226726 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-11-10

No results posted yet for this study

Summary

Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.

Conditions

  • Congenital Myasthenic Syndrome

Interventions

BIOLOGICAL

AlloEx exosomes

This is an intranasal treatment of exosomes derived from mesenchymal stem cells.

Sponsors & Collaborators

  • The Foundation for Orthopaedics and Regenerative Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • United States
  • Antigua and Barbuda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07226726 on ClinicalTrials.gov